AXSM Axsome Therapeutics, Inc.

3.95
-0.15  -4%
Previous Close 4.10
Open 4.10
Price To book 3.30
Market Cap 93.24M
Shares 23,605,000
Volume 276,293
Short Ratio 4.16
Av. Daily Volume 254,163

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 to be initiated 2Q 2017.
AXS-05
Agitation in patients with Alzheimer’s disease (AD)
Initiated July 2015. Expect to complete trial by end of 2017 with interim efficacy analysis due 4Q 2017.
AXS-02 CREATE-1
Complex regional pain syndrome (CRPS)
Phase 3 initiated March 2016. Top-line data due 1Q 2018.
AXS-05 STRIDE-1
Treatment resistant depression
Phase 3 commenced March 2016. Interim analysis due 3Q 2017.
AXS-02 COAST-1
Knee Osteoarthritis Associated with Bone Marrow Lesions
Phase 3 initiation contingent upon resources.
AXS-02
Chronic Low Back Pain Associated with Modic Changes